Logo - RBT.jpg
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
March 11, 2021 09:00 ET | Rénibus Therapeutics Inc.
- Renibus plans to enroll 126 subjects at up to 20 sites across the United States, Canada, Australia, and New Zealand DALLAS, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics®...
Logo - RBT.jpg
Rénibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference
February 25, 2021 09:00 ET | Rénibus Therapeutics Inc.
DALLAS, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rénibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease,...
Logo - RBT.jpg
Renibus Therapeutics Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant
February 16, 2021 09:00 ET | Rénibus Therapeutics Inc.
-With no currently approved therapies for the prevention or treatment of platinum-induced toxicity, RBT-3 has the potential to fill a critical unmet medical need Dallas, Texas, Feb. 16, 2021 ...
Logo - RBT.jpg
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020
October 19, 2020 09:00 ET | Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of...
Logo - RBT.jpg
Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro
October 07, 2020 09:00 ET | Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has...